Shares of Artivion (AORT) tumbled 6.64% in after-hours trading on Monday, following the company's disappointing fourth quarter 2024 earnings report. The medical device maker missed Wall Street's expectations on both the top and bottom lines.
For the quarter, Artivion reported adjusted earnings per share of $0, falling short of analysts' consensus estimate of $0.06 per share. The company also fell short on revenue, generating $97.31 million compared to the $100.82 million projected by analysts.
The weaker-than-expected results weighed on investor sentiment, with Artivion's stock shedding over 6% of its value in extended trading hours after the earnings miss. Investors appeared disappointed by the company's lackluster performance to close out fiscal 2024.